Companies

Sells tirzepatide and the oral GLP-1 pill orforglipron and is testing retatrutide and eloralintide for obesity and diabetes.

Share price

$1,179▲ 41% / 12MUp 41% over 12 months

Analysts say

BuyTarget +6% vs now

Yearly revenue

$80B

Yearly profit

$27B

Tirzepatide, Orforglipron, Retatrutide, Eloralintide, Mazdutide, Teriparatide

See company profile

Sells semaglutide and liraglutide and is developing CagriSema and amycretin for obesity and diabetes.

Share price

$38.64▼ 35% / 12MDown 35% over 12 months

Analysts say

HoldTarget +11% vs now

Yearly revenue

$50B

Yearly profit

$18B

Semaglutide, Liraglutide, CagriSema, Amycretin

See company profile

Maker of tesamorelin (Egrifta) for HIV-related abdominal fat. Delisted in 2025-09 after acquisition by Future Pak.

Tesamorelin

See company profile

Developed bremelanotide (Vyleesi), sold it to Cosette, and now works on next-generation MC4R peptides for obesity.

Share price

$8.60

Analysts say

BuyTarget +818% vs now

Yearly revenue

$13M

Yearly profit

Loss $6.3M

Bremelanotide

See company profile

US company that owns and sells bremelanotide (Vyleesi), acquired from Palatin.

Bremelanotide

See company profile

Develops enlicitide, an oral macrocyclic peptide PCSK9 inhibitor for high cholesterol.

Share price

$146▲ 69% / 12MUp 69% over 12 months

Analysts say

BuyTarget +6% vs now

Yearly revenue

$67B

Yearly profit

$3.2B

Enlicitide

See company profile

Discovers peptide drugs and partnered icotrokinra with Johnson & Johnson and rusfertide with Takeda.

Share price

$144▲ 111% / 12MUp 111% over 12 months

Analysts say

BuyTarget +15% vs now

Yearly revenue

$282M

Yearly profit

$83M

Icotrokinra, Rusfertide

See company profile

Co-markets linaclotide (Linzess) in the US with Ironwood for IBS-C and chronic constipation.

Share price

$279▲ 20% / 12MUp 20% over 12 months

Analysts say

BuyTarget -2% vs now

Yearly revenue

$64B

Yearly profit

$6.3B

Linaclotide

See company profile

Discovered linaclotide (Linzess) and shares US profits on it with AbbVie.

Share price

$3.82▲ 142% / 12MUp 142% over 12 months

Analysts say

BuyTarget +75% vs now

Yearly revenue

$389M

Yearly profit

$130M

Linaclotide

See company profile

Sells icotrokinra (Icotyde), an oral IL-23 receptor peptide for plaque psoriasis discovered with Protagonist.

Share price

$261▲ 37% / 12MUp 37% over 12 months

Analysts say

BuyTarget +8% vs now

Yearly revenue

$98B

Yearly profit

$21B

Icotrokinra

See company profile

Sells afamelanotide (Scenesse) for erythropoietic protoporphyria and is testing it in vitiligo.

Share price

7.94 AUD

Analysts say

BuyTarget +133% vs now

Yearly revenue

96M AUD

Yearly profit

33M AUD

Afamelanotide

See company profile

Developer of elamipretide for Barth syndrome. Its site says the company is now named Mighty Therapeutics.

Elamipretide

See company profile

Austrian company that makes Cerebrolysin, a pig-brain-derived peptide mixture.

Cerebrolysin

See company profile

Danish peptide specialist that co-develops petrelintide with Roche and licensed survodutide to Boehringer Ingelheim.

Share price

266 DKK▼ 36% / 12MDown 36% over 12 months

Analysts say

BuyTarget +77% vs now

Yearly revenue

4.6B DKK

Yearly profit

2.7B DKK

Petrelintide, Survodutide

See company profile

German drugmaker developing survodutide, a glucagon and GLP-1 dual agonist licensed from Zealand Pharma, for obesity and MASH.

Survodutide

See company profile

Sells setmelanotide (Imcivree) for rare genetic and hypothalamic obesity.

Share price

$90.78▼ 9.4% / 12MDown 9.4% over 12 months

Analysts say

BuyTarget +62% vs now

Yearly revenue

$240M

Yearly profit

Loss $210M

Setmelanotide

See company profile

Sells mazdutide, a GLP-1 and glucagon dual agonist licensed from Eli Lilly, in China.

Share price

96.25 HKD

Analysts say

Strong BuyTarget +55% vs now

Yearly revenue

18B HKD

Yearly profit

1.4B HKD

Mazdutide

See company profile

Markets rusfertide (Mimrylo), a hepcidin-mimetic peptide for polycythemia vera, under a deal with Protagonist.

Share price

$18.73▲ 28% / 12MUp 28% over 12 months

Analysts say

BuyTarget +11% vs now

Yearly revenue

$28B

Yearly profit

Loss $1B

Rusfertide

See company profile

Develops MariTide, a monthly antibody-peptide conjugate for obesity, alongside a broad biologics business.

Share price

$415▲ 41% / 12MUp 41% over 12 months

Analysts say

HoldTarget -9% vs now

Yearly revenue

$38B

Yearly profit

$8.7B

MariTide

See company profile

Sells abaloparatide (Tymlos) for osteoporosis in the US. Its site says it is now part of Paratek Pharmaceuticals after a combination announced 2026-03.

Abaloparatide

See company profile

Women's health company that licenses abaloparatide from Radius for Europe and other markets.

Abaloparatide

See company profile

Co-develops the amylin analogue petrelintide for obesity with Zealand Pharma.

Share price

$54.09▲ 19% / 12MUp 19% over 12 months

Analysts say

BuyTarget +1% vs now

Yearly revenue

63B CHF

Yearly profit

12B CHF

Petrelintide

See company profile

Clinical-stage company whose main asset is pemvidutide, a GLP-1 and glucagon dual agonist for MASH and alcohol use disorder.

Share price

$2.61▼ 34% / 12MDown 34% over 12 months

Analysts say

BuyTarget +543% vs now

Yearly revenue

$31K

Yearly profit

Loss $92M

Pemvidutide

See company profile